Literature DB >> 6181062

An equilibrium model of the metastable binding sites of alpha 2-macroglobulin and complement proteins C3 and C4.

S A Khan, B W Erickson.   

Abstract

Two cyclic structures, the 15-membered thiolactone A and the 5-membered lactam P, have been proposed for the metastable binding sites of the serum proteins C3, C4, and alpha 2-macroglobulin. Neither structure alone adequately explains two unusual reactions of these sites, namely, covalent attachment to nucleophiles with liberation of a thiol group and spontaneous hydrolysis (autolysis) of an internal peptide bond. The metastable binding sites of these proteins were modeled with the 15-membered thiolactone 1 (Khan, S. A., and Erickson, B. W. (1981) J. Am. Chem. Soc. 103, 7374-7376) and the isomeric 5-membered lactam 2, which contains an internal pyroglutamyl (Glp) residue. Under physiologic conditions (phosphate-buffered saline, pH 7.3, 37 degrees C), thiolactone 1 and lactam 2 exist in dynamic equilibrium. Since the molar ratio of 2/1 is 11:1 at equilibrium, lactam 2 is 15 kcal/mol more stable than thiolactone 1. The activation energy for isomerization of 1 into 2 is 18 kcal/mol, which is about 5 kcal/mol lower than that for hydrolysis of the acyclic thiolester N,S-diacetyl-L-cysteine methylamide. Part of the chemistry of the metastable binding sites can be explained by an analogous equilibrium between protein structures A and B. Lactam B may be a key intermediate in the biosynthesis of thiolactone A. Under denaturating conditions, thiolactone A could either bind covalently to a receptive surface or isomerize into lactam B, which could undergo spontaneous hydrolysis of the Glu-Glp peptide bond.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6181062

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

Review 1.  The internal thioester and the covalent binding properties of the complement proteins C3 and C4.

Authors:  S K Law; A W Dodds
Journal:  Protein Sci       Date:  1997-02       Impact factor: 6.725

2.  Cis- and trans-acting elements required for constitutive and cytokine-regulated expression of the mouse complement C3 gene.

Authors:  N Kawamura; L Singer; R A Wetsel; H R Colten
Journal:  Biochem J       Date:  1992-05-01       Impact factor: 3.857

Review 3.  The making of a sweet modification: structure and function of O-GlcNAc transferase.

Authors:  John Janetzko; Suzanne Walker
Journal:  J Biol Chem       Date:  2014-10-21       Impact factor: 5.157

Review 4.  The beta-Cys-gamma-Glu thiolester bond in human C3, C4, and alpha 2-macroglobulin.

Authors:  B F Tack
Journal:  Springer Semin Immunopathol       Date:  1983

Review 5.  The alternative pathway of complement.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Springer Semin Immunopathol       Date:  1984

6.  HCF-1 is cleaved in the active site of O-GlcNAc transferase.

Authors:  Michael B Lazarus; Jiaoyang Jiang; Vaibhav Kapuria; Tanja Bhuiyan; John Janetzko; Wesley F Zandberg; David J Vocadlo; Winship Herr; Suzanne Walker
Journal:  Science       Date:  2013-12-06       Impact factor: 47.728

7.  Covalent binding properties of the human complement protein C4 and hydrolysis rate of the internal thioester upon activation.

Authors:  A Sepp; A W Dodds; M J Anderson; R D Campbell; A C Willis; S K Law
Journal:  Protein Sci       Date:  1993-05       Impact factor: 6.725

8.  Classical complement pathway activation by antipneumococcal antibodies leads to covalent binding of C3b to antibody molecules.

Authors:  E J Brown; M Berger; K A Joiner; M M Frank
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

9.  Kinetics of the reaction of thrombin and alpha 2-macroglobulin.

Authors:  R D Feinman; A I Yuan; S R Windwer; D Wang
Journal:  Biochem J       Date:  1985-10-15       Impact factor: 3.857

10.  Molecular basis of complement C3 deficiency in guinea pigs.

Authors:  H S Auerbach; R Burger; A Dodds; H R Colten
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.